ATE345808T1 - Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen - Google Patents

Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen

Info

Publication number
ATE345808T1
ATE345808T1 AT03766078T AT03766078T ATE345808T1 AT E345808 T1 ATE345808 T1 AT E345808T1 AT 03766078 T AT03766078 T AT 03766078T AT 03766078 T AT03766078 T AT 03766078T AT E345808 T1 ATE345808 T1 AT E345808T1
Authority
AT
Austria
Prior art keywords
apolipoprotein
treatment
diseases
derivated
polypeptide
Prior art date
Application number
AT03766078T
Other languages
English (en)
Inventor
Etienne Pays
Luc Vanhamme
Francoise Paturiaux-Hanocq
Philippe Poelvoorde
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Application granted granted Critical
Publication of ATE345808T1 publication Critical patent/ATE345808T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/101—Bovine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT03766078T 2002-08-02 2003-08-04 Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen ATE345808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE200200465 2002-08-02
BE200200649 2002-11-14

Publications (1)

Publication Number Publication Date
ATE345808T1 true ATE345808T1 (de) 2006-12-15

Family

ID=31496437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766078T ATE345808T1 (de) 2002-08-02 2003-08-04 Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen

Country Status (9)

Country Link
US (1) US7585511B2 (de)
EP (1) EP1534320B1 (de)
AT (1) ATE345808T1 (de)
AU (1) AU2003254426A1 (de)
DE (1) DE60309888T2 (de)
DK (1) DK1534320T3 (de)
ES (1) ES2278201T3 (de)
PT (1) PT1534320E (de)
WO (1) WO2004012757A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039645A1 (en) * 2005-10-06 2007-04-12 Vib Vzw African trypanosomiasis therapy with a nanobody-conjugated human trypanolytic factor
EP2101819B1 (de) 2006-11-20 2013-01-09 President and Fellows of Harvard College Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis
WO2009124941A2 (en) * 2008-04-07 2009-10-15 Aarhus Universitet Trypanocidal compounds targeted to trypanosomes interior
WO2010129267A2 (en) 2009-04-27 2010-11-11 University Of Georgia Research Foundation, Inc. Anti-trypanosomal peptides and uses thereof
EP2995303A1 (de) 2009-07-10 2016-03-16 President and Fellows of Harvard College Permanent geladene natrium- und calciumkanalblocker als entzündungshemmende mittel
US20110030078A1 (en) * 2009-07-31 2011-02-03 New York University Trypanosome resistant non-human transgenic animal
WO2011020497A1 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles C-terminal mutant of apolipoprotein l-i and its therapeutical or prophylactic use
WO2011020865A1 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles Apolipoprotein l- i variants and their use
US9023355B2 (en) * 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
US9828637B2 (en) * 2010-04-18 2017-11-28 Wake Forest University Health Sciences Methods of predicting predisposition to or risk of kidney disease
WO2012057934A1 (en) * 2010-10-26 2012-05-03 The Rockefeller University Immunogenic agents
WO2012095508A1 (en) * 2011-01-13 2012-07-19 Universite Libre De Bruxelles Apol3 for use in the treatment of trypanosoma infectious diseases
EP2489365A1 (de) * 2011-02-17 2012-08-22 Université Libre de Bruxelles Wildtyp-Apolipoprotein l-i zur Prävention von Nierenerkrankungen
US20140171365A1 (en) * 2011-03-25 2014-06-19 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof
WO2014078213A2 (en) * 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Modified apol1 polypeptides
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2014100302A1 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. On-column refolding and purifying of lipoproteins
US9751936B2 (en) 2013-03-08 2017-09-05 Regeneron Pharmaceuticals, Inc. Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EP3552488A1 (de) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Tiermodell für nephropathie und mittel zur behandlung davon
WO2017024037A1 (en) 2015-08-03 2017-02-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
MA55307A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques chargés et procédés d'utilisation
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3937945A4 (de) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. Geladene ionenkanalblocker und verfahren zur verwendung
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112021017809A2 (pt) 2019-03-11 2021-11-23 Nocion Therapeutics Inc Bloqueadores de canais iônicos substituídos por éster e métodos para uso
WO2021091585A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP7708777B2 (ja) 2020-03-11 2025-07-15 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
JP2002500039A (ja) * 1998-01-08 2002-01-08 アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド 機能あるヒトリポタンパク質（ａ）を発現するトランスジェニックウサギ

Also Published As

Publication number Publication date
AU2003254426A8 (en) 2004-02-23
EP1534320A2 (de) 2005-06-01
US20060263348A1 (en) 2006-11-23
WO2004012757A2 (en) 2004-02-12
EP1534320B1 (de) 2006-11-22
AU2003254426A1 (en) 2004-02-23
WO2004012757A3 (en) 2004-04-15
DK1534320T3 (da) 2007-04-02
US7585511B2 (en) 2009-09-08
ES2278201T3 (es) 2007-08-01
DE60309888T2 (de) 2007-06-21
DE60309888D1 (de) 2007-01-04
PT1534320E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
DE60309888D1 (de) Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
ATE399014T1 (de) Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE548049T1 (de) Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE515268T1 (de) Verwendung von op-1 zur behandlung von knorpeldefekten
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
ATE551067T1 (de) Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen
ATE315400T1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
ATE549352T1 (de) Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE410174T1 (de) Zusammensetzung zur vorbeugung und behandlung von erkältungskrankheiten
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534320

Country of ref document: EP